Adulthood self-reported cardiovascular risk and ADHD medications: Results from the 2004-2005 national epidemiologic survey on alcohol and related conditions

Journal of Clinical Psychiatry

Volumn 75, Issue 2, 2014, Pages 181-182

  Peyre, Hugo ^a,b,c,d,e   Hoertel, Nicolas ^c,d,e   Hatteea, Hanna ^a,c,d,e   Limosin, Frédéric ^c,d,e   Dubuc, Constance ^a,c,d,e   Delorme, Richard ^a,c,d,e,f  

^a HÔPITAL ROBERT DEBRÉ   (France)

^b ECOLE NORMALE SUPÉRIEURE   (France)

^c Paris Descartes University   (France)

^d UNIVERSITÉ PARIS DESCARTES   (France)

^e INSERM   (France)

^f INSTITUT PASTEUR   (France)

Author keywords

[No Author keywords available]

Indexed keywords

CENTRAL STIMULANT AGENT;

ADULT; ADULTHOOD; ANGINA PECTORIS; ATTENTION DEFICIT DISORDER; CARDIOVASCULAR RISK; CEREBROVASCULAR ACCIDENT; CONTROLLED STUDY; DIETARY INTAKE; DISEASE ASSOCIATION; DISEASE SEVERITY; DRUG EXPOSURE; DRUG SAFETY; FEMALE; HEALTH SURVEY; HEART DEATH; HEART INFARCTION; HUMAN; LETTER; MAJOR CLINICAL STUDY; MALE; MORBIDITY; PATIENT MONITORING; PRIORITY JOURNAL; RISK ASSESSMENT; SELF REPORT; TREATMENT DURATION;

ADULT; AGE OF ONSET; ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY; CARDIOVASCULAR DISEASES; FEMALE; HEALTH SURVEYS; HUMANS; INCIDENCE; MALE; RISK; SELF REPORT; TIME FACTORS; UNITED STATES;

EID: 84896831987     PISSN: 01606689     EISSN: None     Source Type: Journal    
DOI: 10.4088/JCP.13l08736     Document Type: Letter

References (15)

1. Vitiello B. Understanding the risk of using medications for attention deficit hyperactivity disorder with respect to physical growth and cardiovascular function. Child Adolesc Psychiatr Clin N Am. 2008;17(2):459-474, xi. doi:10.1016/j.chc.207.1.010 PubMed
2. Mick E, McManus DD, Goldberg RJ. Meta-analysis of increased heart rate and blood pressure associated with CNS stimulant treatment of ADHD in adults. Eur Neuropsychopharmacol. 2013;23(6):534-541. doi:10.1016/j.euroneuro.2012.06.01 PubMed
3. Vasan RS, Larson MG, Leip EP, et al. Impact of high-normal blood pressure on the risk of cardiovascular disease. N Engl J Med. 2001;345(18):1291-1297. doi:10.1056/NEJMoa03417 PubMed
4. Nissen SE. ADHD drugs and cardiovascular risk. N Engl J Med. 2006;354(14):1445-1448. doi:10.1056/NEJMp068049 PubMed
5. Hammerness PG, Perrin JM, Shelley-Abrahamson R, et al. Cardiovascular risk of stimulant treatment in pediatric attention-deficit/hyperactivity disorder: update and clinical recommendations. J Am Acad Child Adolesc Psychiatry. 2011;50(10):978-990. doi:10.1016/j.jac.201.07.018 PubMed
6. Winterstein AG, Gerhard T, Kubilis P, et al. Cardiovascular safety of central nervous system stimulants in children and adolescents: population based cohort study. BMJ. 2012;345:e4627-e4627. doi:10.136/bmj.e4627 PubMed
7. Cooper WO, Habel LA, Sox CM, et al. ADHD drugs and serious cardiovascular events in children and young adults. N Engl J Med. 2011;365(20):1896-1904. doi:10.1056/NEJMoa10212 PubMed
8. Habel LA, Cooper WO, Sox CM, et al. ADHD medications and risk of serious cardiovascular events in young and middle-aged adults. JAMA. 2011;306(24):2673-2683. doi:10.101/jama.201.1830 PubMed
9. Schelleman H, Bilker WB, Kimmel SE, et al. Methylphenidate and risk of serious cardiovascular events in adults. Am J Psychiatry. 2012;169(2):178-185. doi:10.176/api.ajp.201.1010125 PubMed
10. Holick CN, Turnbull BR, Jones ME, et al. Atomoxetine and cerebrovascular outcomes in adults. J Clin Psychopharmacol. 2009;29(5):453-460. doi:10.1097/JCP.0b013e3181b2b828 PubMed
11. Grant BF, Goldstein RB, Chou SP, et al. Sociodemographic and psychopathologic predictors of first incidence of DSM-IV substance use, mood and anxiety disorders: results from the Wave 2 National Epidemiologic Survey on Alcohol and Related Conditions. Mol Psychiatry. 2009;14(11):1051-1066. doi:10.1038/mp.208.41 PubMed
12. Bernardi S, Faraone SV, Cortese S, et al. The lifetime impact of attention deficit hyperactivity disorder: results from the National Epidemiologic Survey on Alcohol and Related Conditions (NESARC). Psychol Med. 2012;42(4):875-887. doi:10.1017/S03291710153X PubMed
13. Peyre H, Hoertel N, Cortese S, et al. Long-term effects of ADHD medication on adult height: results from the NESARC. J Clin Psychiatry. 2013;74(11):1123-1124. doi:10.408/JCP.13l08580 PubMed
14. World Health Organization. Cardiovascular Diseases (CVDs). Fact Sheet N-317. http://www.who.int/mediacentre/factsheets/fs317/en/index.html Updated March 2013. Accessed July 9, 2013.
15. CADDRA. Canadian Attention Deficit Hyperactivity Disorder Resource Alliance (CADDRA). 3rd ed. Toronto, ON: Canadian ADHD Practice Guidelines; 2011.